Improving practice patterns in patients with newly diagnosed bladder masses treated with transurethral resection

The application period for 2026-27 B/C/C volunteer leadership roles is open now through April 30 | LEARN MORE

By JOM Staff

04.01.22

Transurethral resection (TUR) is the mainstay for diagnosis, staging, and treatment of both high-grade and low-grade nonmuscle invasive bladder cancer (NMIBC). It is reported that 51% of initial transurethral resection of bladder tumors (iTURBT) does not contain muscle, which results in higher rates of clinical upstaging on repeat transurethral resection (reTUR) and worse oncologic outcomes. Presence of muscle on iTURBT specimen and performing reTUR within 6 weeks in high-risk NMIBC aids in accurate staging and, therefore, guides proper treatment.

Read the Article